SCHEMBL2853377

SCHEMBL2853377

CCC(=O)c1ccc(O)c(C(C)C)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 5/20 0.64
HSP90AA1 P07900 4/20 0.64
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
HTT P42858 1/20 0.50
PKM P14618 1/20 0.46
PTGS1 P23219 2/20 0.44
PTGS2 P35354 1/20 0.44
ATM Q13315 1/20 0.44
PPARA Q07869 1/20 0.43
KDM4E B2RXH2 1/20 0.42
DBH P09172 1/20 0.42
GAA P10253 1/20 0.42
RECQL P46063 1/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
THRB P10828 4/20 0.41
THRA P10827 3/20 0.41
GABRA1 P14867 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27959819 0.86 HSP90AA1 (0.64) HSP90AB1HSP90AA1PKMPTGS1PTGS2
SCHEMBL22012694 0.85 HSP90AA1 (0.46) HSP90AB1HSP90AA1ALDH1A1HPGDHTT
SCHEMBL12949976 0.81 HSP90AA1 (0.55) HSP90AB1HSP90AA1HPGDHTTPKM
SCHEMBL8655780 0.81 HSP90AA1 (0.62) HSP90AB1HSP90AA1PTGS1PTGS2KDM4E
SCHEMBL17125210 0.81 MAPT (0.48) HSP90AB1HSP90AA1ALDH1A1HPGDHTT
SCHEMBL27584559 0.79 GABRA1 (0.53) HSP90AB1HSP90AA1ALDH1A1HTTPKM
SCHEMBL383610 0.79 HSP90AA1 (0.60) HSP90AB1HSP90AA1HTTPTGS1PTGS2
SCHEMBL385514 0.79 HSP90AA1 (0.60) HSP90AB1HSP90AA1HTTPKMPTGS1
SCHEMBL30389755 0.79 CA12 (0.58) ALDH1A1HPGDHTTPTGS2ATM
SCHEMBL2991009 0.79 CA12 (0.58) ALDH1A1HPGDHTTPTGS2ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456160-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2010-01-20 EP disclosed
US-6924400-B2 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2005-08-02 US disclosed
EP-1456160-A2 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2004-09-15 EP disclosed
US-20030195259-A1 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-16 US disclosed
WO-2003050067-A2 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195259-A1 Triaromatic vitamin D analogues CYP24A1, CYP2R1, VDR HSP90AB1 2932/4885HSP90AA1 2794/4885ALDH1A1 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.